‘Clinically Proven’ Claim Leaving RB's Brain Health Supplements In US Class Action Settlement
Executive Summary
Settlement in Southern District of Florida federal court includes a consolidated class action complaint against UK firm’s US businesses comprising cases in Florida, New York and California – filed in 2020 over statements the products were “clinically proven” to improve “brain performance” including focus, memory, learning, accuracy, concentration and reasoning.
You may also be interested in...
Prevagen ‘Improves Memory’ Claims Will Be Qualified Under Class Action Settlement
Quincy Bioscience doesn’t admit to “any liability or wrongdoing of any kind associated with the claims alleged” in settlement to complaint in federal court in Florida, but agrees to pay plaintiffs refunds of 30% of the MSRP for its supplements, up to $70 per individual claimant.
Fewer Arrows Left In Quincy's Quiver To Defend Against FTC's Prevagen Supplement Complaint
"There is no need to litigate the same issue again," says District Judge Louis Stanton in granting most of the joint motions by FTC and New York attorney general to strike Quincy Bioscience's proposed defenses. The judge denied other motions, including whether NY state laws are applicable, saying a trial is needed to weigh the evidence.
Reckitt Shaking Up Brain Health Market With Neuriva Dietary Supplement And Mobile App Launch In US
Based on a patented coffee bean extract, the 'clinically proven' Neuriva brain health supplement is being launched by RB onto the US market. The firm has also developed a mobile app to complement the supplement with tailored brain training programs.